Burkard T, Huegle T, Layton JB, Glynn RJ, Bloechliger M, Frey N, Jick SS, Meier CR, Spoendlin J. The risk of incident osteoarthritis of the hand in statin initiators:a sequential cohort study. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1795-805. doi: 10.1002/acr.23616
Burkard T, Bloechliger M, Frey N, Huegle T, Layton JB, Jick SS, Meier CR, Spoendlin J. The risk of incident osteoarthritis of the hand in new users of statins: a propensity score-matched sequential cohort study. Presented at the International Society for Pharmacoepidemiology 2017 Mid-Year Meeting; April 3, 2017. London, United Kingdom.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. Int J Dermatol. 2015 Oct;54(10):e442-5. doi: 10.1111/ijd.12921
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. Letter to the editor. J Am Acad Dermatol. 2015 May;72(5):917-9.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015 Feb;14(2):159-66.
Accortt N, Anthony MS, Schenfeld J, Wheeling T, Hassebroek A, O'Malley CD, Sprafka M. Incidence and prevalence of myasthenia gravis in rheumatoid arthritis patients with and without treatment compared with the general population. Poster presented at the 2014 ACR/ARHP Annual Meeting; November 2014. Boston, MA. [abstract] Arthritis Rheumatol. 2014 Oct; 66(Suppl 1):S895.
Lübbeke A, Rothman KJ, Garavaglia G, Barea C, Christofilopoulos P, Stern R, Hoffmeyer P. Strong association between smoking and the risk of revision in a cohort study of patients with metal-on-metal total hip arthroplasty. J Orthop Res. 2014 Jun;32(6):762-8. doi: 10.1002/jor.22603
Pladevall M, Zografos L, Tatt I, Napalkov P, Andrews E, Perez-Gutthann S. Feasibility evaluation for a rituximab utilization study to be conducted in infusion centers. Poster presented at the 29th International Conference on Pharmacoepidemiology; August 2013.
Macdonald TM, Mackenzie IS, Wei L, Hawkey CJ, Ford I, Perez-Gutthann S. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the Standard care versus Celocoxib Outcome Trial (SCOT). BMJ Open. 2013 Jan 29;3(1):e002295. doi: 10.1136/bmjopen-2012-002295
Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010 Nov 1;11(11):1230-9.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009 Jul;68(7):1177-83. doi: 10.1136/ard.2008.094904
Lunt M, Solomon D, Rothman KJ, Glynn R, Hyrich K, Symmons DP, Stürmer T. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol. 2009 Apr;169(7):909-17.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Presented at the 2008 Annual Meeting of the American College of Rheumatology; October 2008. San Francisco, CA. [abstract] Arthritis Rheum. 2008 Sep; 58(9 Suppl):S782.
Herrinton LJ, Liu L, Shoor S, Mines D. Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Ann Rheum Dis. 2008 Apr;67(4):574-5. doi: 10.1136/ard.2007.075986
Mines D, Gu Y, Liu Q, Horne LN, Harrison MJ. Risk of active tuberculosis (TB) among biologic-naïve RA patients: retrospective cohort study in a US claims database. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):91.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):51.
Mines D, Gu Y, Novelli L, Lui Q, Gelfand J. Risk of CNS demyelinating diseases among patients with psoriasis and rheumatoid arthritis. Poster presented at the 2007 59th Annual Meeting of the American Academy of Neurology; May 2007. Boston, MA. [abstract] Neurology. 2007; 68(12, Suppl 1):A165.
Johannes CB, Chiang CC, Ng EW, Eng PM, Seeger JD, Walker AM. Treatment patterns in patients using biological disease modifying antirheumatic therapy for rheumatoid arthritis. Presented at the 21st International Conference on Pharmacoepidemiology; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Sep; 14(Suppl 2):S195. doi: 10.1002/pds.1136
Eng PM, Johannes CB, Chaing CC, West WA, Seeger JD. Survey of disability, medication use, and medication satisfaction among members with rheumatoid arthritis of a large health care plan database. Poster presented at the 21st International Conference on Pharmacoepidemiology; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Aug; 14(Suppl 2):S5.
Johannes CB, Schneider GA, Walker AM, Viveash D, Wallis WJ. Increased incidence of lymphoma among patients with rheumatic diseases based on automated insurance claims information. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13:S239.
Johannes CB, Schneider GA, Walker AM, Zhao S, Shibata A. Validation of a propensity score developed using claims data in controlling for health status of rheumatic disease patients initiating etanercept compared with other DMARDS. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S16.
Johannes CB, Zhao S, Shibata A, Schneider G, Wallis W, Walker A. Propensity score analysis in balancing underlying disease severity among rheumatic disease patients treated with etanercept or another DMARD. Poster presented at the American College of Rheumatology Annual Scientific Meeting; 2004.
Johannes CB, Schneider G, Aygun AC, L'Italien GJ, Viveash D, Wallis WJ. Time to first disease modifying anti-rheumatic drug therapy (DMARD) among rheumatic disease patients in a population based study. Poster presented at the American College of Rheumatology Annual Scientific Meeting; 2003.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2
Gilsenan AW, Morris LS, Carlson AM. Association between quality of sleep and NSAID use for osteoarthritis in older patients. Presented at the American Society of Consultant Pharmacists National Meeting; 1996. Nashville, TN.
Grodstein F, Rothman KJ. Epidemiology of pelvic inflammatory disease. Epidemiology. 1994 Mar;5(2):234-42.